1. Which of the following precisely identifies the ribosomal target of macrolide antibiotics and the molecular site within that target to which macrolides bind?
A) The 30S ribosomal subunit, at the decoding A site on 16S rRNA, where macrolides prevent aminoacyl-tRNA from entering and delivering amino acids to the elongating peptide chain
B) The 50S ribosomal subunit, at the peptidyl transferase center, where macrolides directly inhibit the catalytic reaction that forms peptide bonds between adjacent amino acids
C) The 50S ribosomal subunit, at domain V of the 23S rRNA, where macrolides occlude the nascent peptide exit tunnel and block translocation of the growing peptide chain from the A site to the P site
D) The 30S ribosomal subunit, at the 16S rRNA decoding center, where macrolides cause misreading of mRNA codons and insertion of incorrect amino acids into the growing peptide chain
E) The 50S ribosomal subunit, at the L4 and L22 ribosomal proteins flanking the peptide exit tunnel, where macrolides covalently cross-link these proteins and permanently seal the tunnel
ANSWER: C
Rationale:
Macrolides bind specifically to domain V of the 23S rRNA component of the 50S ribosomal subunit. Their binding site is located within the nascent peptide exit tunnel, proximal to the peptidyl transferase center. By occupying this tunnel, macrolides physically obstruct movement of the elongating peptide chain from the acceptor (A) site to the peptidyl (P) site — the translocation step — stalling protein synthesis after only a few amino acids have been incorporated. This accounts for the bacteriostatic activity of macrolides against most susceptible organisms and explains why the MLSB resistance mechanism (erm methylase methylating A2058 in the 23S rRNA) abolishes macrolide binding: the modification is at the precise 23S rRNA contact site.
Option A: Option A is incorrect because the 30S subunit and 16S rRNA decoding A site are the targets of aminoglycosides and tetracyclines, not macrolides; tetracyclines block aminoacyl-tRNA entry while aminoglycosides cause misreading.
Option B: Option B is incorrect because macrolides do not directly inhibit the peptidyl transferase reaction itself; they act downstream by blocking the exit tunnel and translocation rather than the bond-forming step at the transferase center.
Option D: Option D is incorrect because mRNA misreading through 16S rRNA decoding center disruption is the mechanism of aminoglycosides, not macrolides; aminoglycosides bind the 30S subunit at a site that promotes miscoding.
Option E: Option E is incorrect because macrolide binding to the 23S rRNA is reversible, not covalent; macrolides do not cross-link L4 and L22 ribosomal proteins, and cross-linking is not a recognized mechanism for any clinically used antibiotic class.
2. Azithromycin's clinical dosing advantages — once-daily administration and short-course regimens — are directly attributable to a structural modification that distinguishes it from erythromycin and clarithromycin. Which of the following correctly identifies that structural feature and the pharmacokinetic consequence most directly responsible for short-course efficacy?
A) Azithromycin is an azalide: its 15-membered lactone ring contains an inserted nitrogen atom, a modification that drives extensive intracellular accumulation in phagocytic cells, producing tissue concentrations 10 to 100 times higher than concurrent serum levels and a tissue half-life of approximately 68 hours that sustains antibacterial activity at infection sites long after each dose
B) Azithromycin is a 6-O-methyl derivative of erythromycin whose methyl substitution eliminates acid lability and generates an active 14-hydroxy metabolite with a tissue half-life exceeding 48 hours, enabling once-daily dosing and Z-pack regimens
C) Azithromycin is a 16-membered macrolide whose expanded ring confers greater lipophilicity than erythromycin, allowing passive diffusion across cell membranes and accumulation in adipose tissue, from which it is slowly released over days to maintain effective plasma concentrations
D) Azithromycin undergoes extensive enterohepatic recirculation: biliary-excreted drug is reabsorbed from the intestine, maintaining plasma concentrations above the minimum inhibitory concentration for respiratory pathogens for 7 to 10 days after a standard course ends
E) Azithromycin is acid-stable and achieves oral bioavailability approaching 80% because its nitrogen-containing ring buffers gastric acid, allowing complete absorption from the stomach rather than the small intestine, which accounts for its higher tissue delivery compared to erythromycin
ANSWER: A
Rationale:
Azithromycin is classified as an azalide because its 15-membered lactone ring incorporates a nitrogen atom into the ring structure — a modification absent from the 14-membered rings of erythromycin and clarithromycin. This structural change drives the defining pharmacokinetic feature of azithromycin: avid uptake by phagocytic cells including alveolar macrophages, polymorphonuclear neutrophils, and monocytes. Intracellular tissue concentrations reach 10 to 100 times concurrent serum levels, and the resulting tissue half-life of approximately 68 hours sustains drug concentrations at infection sites for days after each dose and days to more than a week after completing a course. This reservoir in phagocytes — which migrate to sites of infection — is the pharmacokinetic basis for both the 5-day Z-pack regimen for respiratory infections and single-dose therapy for Chlamydia trachomatis.
Option B: Option B is incorrect because the 6-O-methyl derivative with a 14-hydroxy active metabolite describes clarithromycin, not azithromycin; clarithromycin's 6-O-methylation improves acid stability and generates 14-hydroxyclarithromycin.
Option C: Option C is incorrect because azithromycin has a 15-membered ring, not 16-membered; 16-membered macrolides (spiramycin, josamycin) are a distinct subclass not in standard clinical use in the United States, and the mechanism described — adipose tissue reservoir releasing drug into plasma — does not account for azithromycin's tissue pharmacokinetics.
Option D: Option D is incorrect because enterohepatic recirculation is not the mechanism of azithromycin's prolonged duration; azithromycin is excreted unchanged in bile, but active phagocytic cell accumulation — not intestinal reabsorption — explains its sustained tissue activity.
Option E: Option E is incorrect because azithromycin's oral bioavailability averages approximately 37%, not 80%; this reflects extensive first-pass tissue uptake from the gut wall and portal circulation as the drug is absorbed, not buffering of gastric acid by a nitrogen-containing ring.
3. Among erythromycin, clarithromycin, and azithromycin, which agent is the most potent inhibitor of cytochrome P450 3A4 (CYP3A4), and what is the biochemical mechanism that distinguishes its inhibition from simple competitive inhibition?
A) Azithromycin is the most potent CYP3A4 inhibitor among the three macrolides because its nitrogen-containing azalide ring forms a coordinate bond with the heme iron of CYP3A4, creating an irreversible complex; this makes azithromycin the highest-risk agent for drug interactions in patients on CYP3A4-sensitive medications
B) Clarithromycin is the most potent CYP3A4 inhibitor because its 14-hydroxyclarithromycin active metabolite binds covalently to the CYP3A4 apoprotein, permanently inactivating enzyme molecules; erythromycin and azithromycin are reversible competitive inhibitors with lower interaction potential
C) All three macrolides inhibit CYP3A4 by identical mechanism-based inhibition; the rank order of potency is clinically irrelevant because all three produce the same degree of enzyme inactivation per milligram of administered dose
D) Azithromycin and erythromycin are equipotent CYP3A4 inhibitors that both form stable nitrosoalkane-iron complexes; clarithromycin does not inhibit CYP3A4 because its 6-O-methyl group sterically blocks access to the enzyme active site
E) Erythromycin is the most potent macrolide CYP3A4 inhibitor; it undergoes CYP3A4-mediated metabolism to a nitrosoalkane intermediate that forms a stable inactive complex with the ferrous iron of the enzyme — mechanism-based inhibition that is irreversible and requires new CYP3A4 synthesis for recovery of enzyme activity
ANSWER: E
Rationale:
Erythromycin is the most potent CYP3A4 inhibitor among the three major macrolides. The mechanism is mechanism-based (also termed suicide or irreversible) inhibition: erythromycin is first metabolized by CYP3A4 to a reactive nitrosoalkane intermediate, which then forms a stable, inactive coordinate complex with the ferrous (Fe²⁺) form of the CYP3A4 heme iron. This permanently inactivates the enzyme molecule — recovery of CYP3A4 activity requires de novo synthesis of new enzyme protein and is independent of erythromycin plasma half-life. Clarithromycin inhibits CYP3A4 by the same nitrosoalkane mechanism and is a significant inhibitor, though somewhat less potent than erythromycin. Azithromycin, because it is not substantially demethylated by CYP3A4, does not generate the nitrosoalkane intermediate and produces negligible CYP3A4 inhibition at clinical doses. This hierarchy — erythromycin > clarithromycin >> azithromycin — is the pharmacokinetic basis for selecting azithromycin in polypharmacy patients on CYP3A4-sensitive drugs.
Option A: Option A is incorrect because azithromycin is the least potent CYP3A4 inhibitor among the three, not the most potent; its azalide nitrogen does not form an inhibitory coordinate bond with CYP3A4 heme iron in the same manner as erythromycin's nitrosoalkane intermediate.
Option B: Option B is incorrect because the 14-hydroxyclarithromycin metabolite does not covalently modify the CYP3A4 apoprotein; both clarithromycin and erythromycin inhibit CYP3A4 through the same nitrosoalkane-Fe²⁺ complex mechanism, with erythromycin being more potent.
Option C: Option C is incorrect because the three macrolides differ substantially in CYP3A4 inhibitory potency; the rank order (erythromycin > clarithromycin >> azithromycin) is of major clinical significance in drug interaction management.
Option D: Option D is incorrect because azithromycin does not form a nitrosoalkane-iron complex and is not an equipotent CYP3A4 inhibitor with erythromycin; clarithromycin does inhibit CYP3A4 by a nitrosoalkane mechanism similar to erythromycin, and the 6-O-methyl group does not sterically block this pathway.
4. Clarithromycin is distinguished from erythromycin by a hepatic metabolic pathway that produces an active metabolite with clinically relevant antibacterial activity. Which of the following correctly identifies this metabolite and the specific spectrum extension it provides?
A) Clarithromycin is metabolized to N-desmethylclarithromycin, which has enhanced activity against Mycobacterium avium complex compared to the parent compound and is the principal species responsible for clarithromycin's efficacy in MAC treatment regimens
B) Clarithromycin is metabolized to 14-hydroxyclarithromycin, an active metabolite that contributes antibacterial activity against Haemophilus influenzae and extends clarithromycin's effective respiratory spectrum beyond that of erythromycin, which has limited reliable activity against H. influenzae
C) Clarithromycin is metabolized to a 3-keto derivative that is active against Legionella pneumophila but inactive against gram-positive organisms; the parent compound covers gram-positive pathogens while the metabolite covers atypical organisms, creating dual-mechanism empiric coverage for community-acquired pneumonia
D) Clarithromycin undergoes hepatic O-dealkylation to a compound that inhibits bacterial DNA gyrase in addition to ribosomal binding, providing dual mechanism activity against fluoroquinolone-susceptible organisms when clarithromycin is used at full therapeutic doses
E) Clarithromycin is metabolized to erythromycin by hepatic demethylation; this conversion explains why clarithromycin's antibacterial spectrum is essentially identical to erythromycin and why the two agents can be used interchangeably in all clinical indications
ANSWER: B
Rationale:
Clarithromycin undergoes hepatic metabolism to its primary active metabolite, 14-hydroxyclarithromycin. This metabolite retains antibacterial activity and importantly demonstrates meaningful activity against Haemophilus influenzae, extending clarithromycin's effective respiratory spectrum compared to erythromycin. Erythromycin has limited and unreliable activity against H. influenzae, making clarithromycin's metabolite-mediated H. influenzae coverage a clinically significant distinction — particularly relevant in respiratory tract infections such as acute exacerbations of COPD and sinusitis, where H. influenzae is a major pathogen. Clarithromycin also achieves oral bioavailability of approximately 50 to 55% and supports twice-daily dosing due to a half-life of approximately 3 to 7 hours.
Option A: Option A is incorrect because N-desmethylclarithromycin is not the recognized active metabolite of clarithromycin; 14-hydroxyclarithromycin is the established active metabolite, and while clarithromycin is indeed active against MAC, this activity resides in both the parent compound and the 14-hydroxy metabolite acting together.
Option C: Option C is incorrect because clarithromycin's active metabolite is 14-hydroxyclarithromycin, not a 3-keto derivative; clarithromycin does not have dual-mechanism activity against DNA gyrase, and its spectrum is not divided between parent and metabolite in the manner described.
Option D: Option D is incorrect because clarithromycin and its metabolite do not inhibit bacterial DNA gyrase; that mechanism belongs to fluoroquinolones, and macrolides act exclusively through 50S ribosomal binding — no macrolide metabolite has fluoroquinolone-like activity.
Option E: Option E is incorrect because clarithromycin is not converted to erythromycin by hepatic metabolism; it is a chemically distinct 6-O-methyl derivative of erythromycin, and its metabolite is 14-hydroxyclarithromycin — which has its own spectrum profile, including H. influenzae activity that erythromycin lacks.
5. A Streptococcus pneumoniae isolate is reported erythromycin-resistant, clindamycin-susceptible, with a negative D-zone test. This pattern is consistent with the M phenotype of macrolide resistance. Which of the following precisely describes the M phenotype mechanism and correctly distinguishes it from MLSB resistance?
A) The M phenotype is caused by constitutive expression of erm methylase that has been modified to methylate only the macrolide binding site while leaving the adjacent clindamycin contact residues unmethylated; MLSB resistance involves a wild-type erm methylase that methylates both macrolide and lincosamide contact sites simultaneously
B) The M phenotype results from a point mutation in the 23S rRNA at position 2058 that specifically disrupts macrolide binding without affecting clindamycin binding, because clindamycin contacts position 2059 rather than 2058; MLSB resistance involves erm methylase that methylates both positions simultaneously
C) The M phenotype and MLSB resistance are both caused by erm methylase; the distinction is purely quantitative — M phenotype organisms express lower levels of erm methylase, producing low-level macrolide resistance, while MLSB organisms express higher levels producing cross-resistance to all three drug classes
D) The M phenotype is conferred by the mef gene, which encodes a proton-motive force-dependent efflux pump that actively transports macrolides out of the bacterial cytoplasm; clindamycin is not a substrate for this pump and therefore accumulates normally within the cell, explaining the selective macrolide resistance without cross-resistance to lincosamides
E) The M phenotype is caused by enzymatic inactivation of macrolides by a phosphotransferase encoded on a mobile genetic element; clindamycin is not inactivated because it lacks the hydroxyl group on the lactone ring that the phosphotransferase requires as a substrate
ANSWER: D
Rationale:
The M (macrolide-only) resistance phenotype in Streptococcus pneumoniae and other organisms is mediated by the mef gene, which encodes a proton-motive force-dependent efflux pump. This pump transports macrolide antibiotics — erythromycin, clarithromycin, azithromycin — out of the bacterial cytoplasm, maintaining intracellular drug concentrations below inhibitory levels. Critically, clindamycin (a lincosamide) is not a substrate for the mef pump; it is not actively effluxed and therefore accumulates normally within the bacterium to inhibit the 50S ribosomal target. This substrate specificity is the mechanistic basis for the M phenotype pattern: macrolide resistance with preserved clindamycin susceptibility. In contrast, MLSB resistance mediated by erm methylase modifies the shared ribosomal binding site (A2058 in 23S rRNA) used by macrolides, lincosamides, and streptogramin B simultaneously, producing cross-resistance to all three classes. The negative D-zone test in this isolate confirms the M phenotype (mef-mediated) rather than inducible MLSB resistance — inducible erm would produce a positive D-zone.
Option A: Option A is incorrect because the M phenotype is not caused by a modified erm methylase; it is caused by the mef efflux pump, a completely distinct resistance mechanism with no methylase activity.
Option B: Option B is incorrect because the M phenotype is not caused by a point mutation in 23S rRNA; 23S rRNA mutations at positions 2058 and 2059 are associated with MAC resistance to macrolides and with macrolide-resistant Mycoplasma pneumoniae — not with the M phenotype in pneumococcus.
Option C: Option C is incorrect because M phenotype and MLSB resistance are mechanistically distinct, not quantitatively different expressions of the same erm gene; the M phenotype is efflux-mediated (mef), while MLSB is methylase-mediated (erm).
Option E: Option E is incorrect because enzymatic phosphorylation of macrolides has been described in some organisms but is not the mechanism of the M phenotype in S. pneumoniae; the M phenotype is specifically defined by mef-mediated efflux.
6. The MLSB resistance phenotype confers simultaneous resistance to macrolides, lincosamides, and streptogramin B antibiotics. Which of the following correctly identifies the gene product responsible for MLSB resistance, the specific molecular modification it produces, and why that single modification abolishes activity of three structurally distinct antibiotic classes?
A) The cfr gene encodes an rRNA methyltransferase that methylates position A2503 in the 23S rRNA, a modification that disrupts binding of macrolides, lincosamides, and streptogramin B by collapsing the peptide exit tunnel into a conformation that physically excludes all three drug classes regardless of their individual contact residues
B) The mef gene encodes an efflux pump whose substrate-binding pocket recognizes a structural motif shared by macrolides, lincosamides, and streptogramin B; binding of any of the three drug classes to this shared motif triggers active transport out of the cell, and the breadth of efflux explains the pan-class resistance pattern
C) The erm gene encodes a methylase enzyme that methylates the N-6 position of adenine at position 2058 (A2058) in the 23S rRNA of the 50S subunit — the binding site shared by macrolides, lincosamides, and streptogramin B antibiotics; this single 23S rRNA modification reduces the affinity of all three drug classes for their overlapping ribosomal contact region simultaneously
D) The erm gene encodes a ribosome protection protein that binds to the 50S subunit and induces a conformational change in the L4 ribosomal protein, narrowing the peptide exit tunnel; this narrowed tunnel sterically excludes the bulky lactone rings of macrolides, lincosamides, and streptogramin B, all of which require a wide tunnel for binding
E) The vanA gene, when expressed in gram-positive organisms, reprograms peptidoglycan synthesis and simultaneously alters the charge distribution of the 23S rRNA, reducing the electrostatic affinity of macrolides, lincosamides, and streptogramin B for their binding site by disrupting the magnesium ion coordination normally required for drug-rRNA contact
ANSWER: C
Rationale:
MLSB resistance is mediated by erm (erythromycin ribosome methylation) genes, which encode methylase enzymes that add a methyl group to the N-6 position of adenine at position 2058 (A2058) in the 23S rRNA of the 50S ribosomal subunit. This single adenine residue sits at the core of the overlapping binding region contacted by macrolides, lincosamides (clindamycin), and streptogramin B antibiotics. Because all three drug classes interact with the same A2058-containing region of the 23S rRNA as part of their ribosomal binding, the single methylation event reduces the binding affinity of all three classes simultaneously — producing the pan-class MLSB resistance pattern. Erm genes are carried on plasmids and transposons, facilitating horizontal transfer among gram-positive organisms. MLSB resistance can be constitutive (always expressed) or inducible (triggered by macrolide exposure, detected by the D-zone test).
Option A: Option A is incorrect because the cfr gene methylates position A2503 and confers resistance to a different combination of drug classes (phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A — the PhLOPSA phenotype), not specifically MLSB resistance; the mechanism described for A2503 modification is also inaccurate.
Option B: Option B is incorrect because the mef gene encodes a macrolide-specific efflux pump that does not transport lincosamides or streptogramin B; mef-mediated resistance produces the M phenotype (macrolide-only resistance), not MLSB cross-resistance.
Option D: Option D is incorrect because erm encodes a methylase that modifies 23S rRNA, not a ribosome protection protein; ribosome protection is the mechanism of tetracycline resistance proteins (TetM, TetO), and L4 protein narrowing of the peptide exit tunnel is associated with low-level intrinsic macrolide resistance, not erm-mediated MLSB resistance.
Option E: Option E is incorrect because vanA encodes enzymes involved in D-Ala-D-Lac peptidoglycan reprogramming for vancomycin resistance and has no known mechanistic connection to 23S rRNA modification or MLSB resistance; linking vanA to macrolide resistance is pharmacologically incorrect.
7. Erythromycin is sometimes administered at sub-antimicrobial doses for a non-infectious indication. Which of the following correctly identifies the receptor mechanism underlying this clinical application and explains why azithromycin produces fewer gastrointestinal adverse effects than erythromycin despite both agents being administered orally?
A) Erythromycin is a potent agonist at motilin receptors in the gastrointestinal tract; motilin is an enteric hormone that drives interdigestive gastric and small bowel contractions, and erythromycin's structural mimicry of motilin accelerates gastric emptying — exploitable therapeutically for gastroparesis; azithromycin has substantially lower motilin receptor affinity, producing fewer motility-driven adverse effects at therapeutic doses
B) Erythromycin activates muscarinic M3 receptors on gastrointestinal smooth muscle by inhibiting acetylcholinesterase in the myenteric plexus, increasing local acetylcholine concentrations; this prokinetic effect is used for gastroparesis; azithromycin does not inhibit acetylcholinesterase because its nitrogen-containing azalide ring sterically blocks the enzyme active site
C) Erythromycin blocks dopamine D2 receptors in the gastric antrum and the chemoreceptor trigger zone, accelerating gastric emptying and explaining both its prokinetic utility and its tendency to cause nausea through central D2 blockade; azithromycin does not block D2 receptors and therefore lacks both the prokinetic benefit and the nausea risk
D) Erythromycin activates 5-HT4 receptors on enteric neurons, stimulating release of acetylcholine from the myenteric plexus; this 5-HT4 agonism is the same mechanism used by cisapride and metoclopramide, and erythromycin's QTc-prolonging effect is a direct consequence of 5-HT4 receptor activation in cardiac tissue; azithromycin lacks 5-HT4 affinity
E) Erythromycin directly stimulates smooth muscle contraction through calcium channel activation in the gastrointestinal wall, bypassing receptor-mediated pathways entirely; azithromycin has lower GI adverse effects because its larger molecular size reduces passive diffusion across the intestinal epithelium, limiting the drug's access to smooth muscle calcium channels
ANSWER: A
Rationale:
Macrolides, particularly erythromycin, produce their gastrointestinal motility effects through agonism at motilin receptors. Motilin is a peptide hormone secreted by enterochromaffin-like cells of the small intestine that normally triggers the migrating motor complex (MMC) — the interdigestive contractions that propagate through the stomach and small bowel between meals. Erythromycin's structural similarity to motilin allows it to bind and activate motilin receptors, stimulating gastric and intestinal smooth muscle contraction and accelerating gastric emptying. This effect has been deliberately exploited at sub-antimicrobial doses (1–3 mg/kg IV or 125–250 mg orally) as a prokinetic agent for diabetic gastroparesis and for facilitating enteral feeding in critically ill patients with delayed gastric emptying. Azithromycin has substantially lower motilin receptor affinity than erythromycin, which accounts for its considerably better gastrointestinal tolerability.
Option B: Option B is incorrect because erythromycin does not inhibit acetylcholinesterase; its GI prokinetic effect is mediated through direct motilin receptor agonism, not cholinergic amplification.
Option C: Option C is incorrect because D2 receptor blockade is the mechanism of prokinetic drugs such as metoclopramide and domperidone — not macrolides; erythromycin's prokinetic effect is motilin receptor-mediated, and its nausea is also largely a consequence of motilin agonism causing excessive peristaltic activity rather than central D2 blockade.
Option D: Option D is incorrect because 5-HT4 receptor agonism is the mechanism of cisapride and tegaserod — not macrolides; erythromycin's prokinetic effect is motilin-mediated, and QTc prolongation from macrolides arises from hERG/IKr potassium channel block, not 5-HT4 activation.
Option E: Option E is incorrect because erythromycin does not stimulate GI smooth muscle through direct calcium channel activation; the mechanism is receptor-mediated motilin agonism, and azithromycin's lower GI burden reflects receptor affinity differences, not molecular size-limited mucosal diffusion.
8. A clinical microbiology laboratory performs a D-zone test on a Staphylococcus aureus isolate that is erythromycin-resistant but clindamycin-susceptible by standard disk diffusion. The result shows flattening of the clindamycin inhibition zone on the side adjacent to the erythromycin disk. Which of the following correctly interprets this finding and states the appropriate laboratory reporting action?
A) The D-zone test result indicates constitutive MLSB resistance; flattening of the clindamycin zone confirms that erm methylase is being expressed continuously regardless of erythromycin presence; the isolate should be reported as susceptible to clindamycin because the erythromycin disk is merely an artifact of the test setup
B) The D-zone test result indicates the M phenotype; flattening of the clindamycin inhibition zone occurs because the mef efflux pump is upregulated by proximity to the erythromycin disk and begins to efflux clindamycin as a secondary substrate; the isolate should be reported as having macrolide-only resistance with clindamycin susceptibility confirmed
C) The D-zone test result indicates that the organism produces a bifunctional enzyme that inactivates both erythromycin and clindamycin; the D-shaped zone forms because inactivated erythromycin diffusing from the disk reduces the inactivation burden on clindamycin adjacent to it; the isolate is resistant to both agents
D) The D-zone test result is indeterminate; flattening of the clindamycin zone is a non-specific finding that can result from antagonism between any two antibiotics placed in proximity on an agar plate; repeat testing with greater disk separation is required before a resistance classification can be made
E) The D-zone test result indicates inducible MLSB resistance; the subinhibitory gradient of erythromycin diffusing from the erythromycin disk induces erm methylase expression in adjacent bacteria, blunting the clindamycin zone on that side; the isolate should be reported as clindamycin-resistant regardless of its MIC, because in vivo clindamycin exposure can select for constitutive erm mutants causing treatment failure
ANSWER: E
Rationale:
A positive D-zone test — defined as flattening of the clindamycin inhibition zone on the side facing the erythromycin disk, producing a D-shape — indicates inducible MLSB resistance. The test exploits the fact that erythromycin is an inducer of erm methylase expression: as erythromycin diffuses outward from its disk, organisms in the subinhibitory erythromycin gradient zone adjacent to the clindamycin disk have their erm genes induced. These organisms now express erm methylase, methylate the A2058 residue in their 23S rRNA, and become resistant to clindamycin — producing the characteristic zone flattening. In standard susceptibility testing without an erythromycin inducer, the same organisms appear clindamycin-susceptible. A positive D-zone test predicts that clindamycin therapy may select for constitutive erm-expressing mutants in vivo, where clindamycin itself can act as a partial inducer; treatment failure has been documented under these circumstances. Clinical microbiology standards therefore require reporting such isolates as clindamycin-resistant regardless of the numeric MIC result.
Option A: Option A is incorrect because constitutive MLSB resistance produces complete, symmetrical blunting of the clindamycin zone (no D-shape, just reduced or absent inhibition) — not the D-shaped flattening on one side that characterizes the positive D-zone test for inducible resistance; and the reporting action for a positive test is clindamycin-resistant, not susceptible.
Option B: Option B is incorrect because the D-zone test is not designed to detect mef efflux; mef-mediated M phenotype organisms produce macrolide resistance without cross-resistance to clindamycin, and a negative D-zone test (not a positive one) accompanies the M phenotype.
Option C: Option C is incorrect because a bifunctional enzyme inactivating both drugs is not the interpretation of a D-zone positive; the D-zone test specifically detects inducible erm methylase, and the mechanism described — erythromycin inactivation reducing the clindamycin inactivation burden — is pharmacologically unfounded.
Option D: Option D is incorrect because the D-zone test is a standardized, validated microbiological procedure with specific interpretive criteria; the D-shaped flattening is not a non-specific artifact of disk proximity but a specific indicator of inducible erm expression, and repeat testing with greater disk separation would eliminate the induction gradient and produce a falsely reassuring result.
9. Macrolide antibiotics carry a risk of potentially fatal cardiac arrhythmia. Which of the following correctly identifies the ion channel mechanism responsible for macrolide-associated QTc prolongation and lists the patient characteristics that most substantially amplify this risk?
A) Macrolides block the L-type calcium channel (ICa-L) during phase 2 of the ventricular action potential, prolonging the plateau phase and shortening repolarization reserve; the risk is amplified by hypercalcemia, concurrent calcium channel blocker use, and right bundle branch block
B) Macrolides block the rapid component of the delayed rectifier potassium current (IKr), encoded by the hERG gene, delaying ventricular repolarization and prolonging the QT interval; risk is most substantially amplified by pre-existing QT prolongation, hypokalemia, hypomagnesemia, female sex, bradycardia, and concurrent use of other QT-prolonging agents
C) Macrolides activate the late sodium current (INa-late) during phase 3 of the ventricular action potential, prolonging repolarization and creating early afterdepolarizations; the risk is highest in patients with heart failure with reduced ejection fraction because INa-late is upregulated in failing myocardium
D) Macrolides inhibit the slow component of the delayed rectifier potassium current (IKs), encoded by KCNQ1, reducing repolarization reserve; this effect is reversed by sympathetic stimulation and is therefore most dangerous during vagally mediated bradycardia episodes in patients with sinus node dysfunction
E) Macrolides directly activate the inward rectifier potassium current (IK1), hyperpolarizing ventricular myocytes and paradoxically increasing vulnerability to triggered activity by creating a large repolarization gradient between adjacent cells; the risk is highest in patients with left ventricular hypertrophy
ANSWER: B
Rationale:
Macrolides prolong the cardiac QT interval by blocking IKr — the rapid component of the delayed rectifier potassium current encoded by the hERG (human ether-a-go-go-related gene) channel. IKr is a major repolarizing current during phase 3 of the ventricular action potential; its inhibition delays repolarization, prolongs the QT interval, and creates the electrophysiological substrate for early afterdepolarizations that can trigger torsades de pointes (TdP) — a polymorphic ventricular tachycardia that may degenerate into ventricular fibrillation. Among the three major macrolides, azithromycin and erythromycin carry the greatest QT-prolonging potential; clarithromycin also prolongs the QT interval. Patient characteristics that most substantially amplify this risk include: pre-existing QT prolongation (any baseline cause), hypokalemia and hypomagnesemia (both reduce IKr independently, narrowing repolarization reserve), female sex (an independent risk factor for drug-induced TdP, likely due to baseline longer QTc), bradycardia (longer cycle lengths at slower heart rates increase QT duration), and concurrent use of other QT-prolonging agents. A widely cited 2012 cohort study by Ray et al. demonstrated significantly increased rates of cardiovascular death with azithromycin compared to amoxicillin, concentrated in patients with pre-existing cardiovascular risk factors.
Option A: Option A is incorrect because macrolides do not block L-type calcium channels; L-type calcium channel blockade shortens rather than prolongs the QT interval and is the mechanism of calcium channel blocker antiarrhythmic drugs; hypercalcemia is associated with QT shortening, not prolongation.
Option C: Option C is incorrect because macrolide QTc prolongation is caused by IKr block, not late sodium current activation; INa-late enhancement is the mechanism of QT prolongation by ranolazine and is relevant in certain cardiomyopathies, but it is not the macrolide mechanism.
Option D: Option D is incorrect because macrolides target IKr (hERG), not IKs (KCNQ1/KCNE1); IKs block is the mechanism of some class III antiarrhythmics (azimilide) and congenital long QT syndrome type 1, but not macrolide-induced QTc prolongation.
Option E: Option E is incorrect because macrolides do not activate IK1 (the inward rectifier); IK1 activation would hyperpolarize and stabilize myocytes rather than cause triggered arrhythmia, and this is not a recognized mechanism of drug-induced TdP.
10. A resident proposes substituting azithromycin monotherapy for ceftriaxone in a patient with pneumococcal bacteremia, reasoning that azithromycin's high tissue concentrations should provide superior antibacterial activity. Which of the following correctly identifies the pharmacokinetic limitation that makes azithromycin unreliable for bloodstream infection?
A) Azithromycin is eliminated exclusively by renal filtration, and the glomerular filtration rate in bacteremic patients is commonly reduced due to sepsis-associated acute kidney injury; this reduces azithromycin clearance and paradoxically increases serum concentrations to toxic levels that are bactericidal but cause cardiac arrhythmia and ototoxicity before bacteremia is cleared
B) Azithromycin's oral bioavailability is less than 5% during systemic infection because sepsis-associated intestinal edema impairs drug absorption across the mucosal epithelium; parenteral administration would restore adequate serum concentrations, but the IV formulation has been discontinued in the United States
C) Azithromycin is bacteriostatic rather than bactericidal, and treatment of bacteremia requires bactericidal antibiotics to prevent persistent seeding of the bloodstream from the primary infection focus; only bactericidal agents can achieve the log-phase bacterial kill required to clear bloodstream infection within the 24-hour window before septic shock ensues
D) Azithromycin's high tissue concentrations are achieved at the expense of low serum concentrations — substantially lower than concurrent intracellular tissue levels — and bacteria circulating in the bloodstream encounter serum drug concentrations, not tissue concentrations; serum azithromycin levels are insufficient to reliably maintain antibacterial activity against organisms residing in the vascular compartment
E) Azithromycin distributes rapidly out of serum into tissues within minutes of administration, creating a transiently very high peak serum concentration that exceeds the minimum inhibitory concentration for pneumococcus; however, because azithromycin is concentration-independent (time-dependent) in its killing kinetics, this brief peak is pharmacodynamically ineffective against bacteremic organisms
ANSWER: D
Rationale:
Azithromycin's defining pharmacokinetic feature — intracellular tissue concentrations 10 to 100 times higher than concurrent serum levels — is a significant advantage for infections within tissues where phagocytes deliver the drug, but it is a fundamental limitation for bacteremia. Bacteria circulating in the bloodstream reside in the plasma and encounter serum drug concentrations, not the high intracellular tissue concentrations stored within macrophages and neutrophils. Because azithromycin serum concentrations are substantially lower than tissue levels, and because effective treatment of bacteremia requires sustained antibacterial drug concentrations in the blood compartment, azithromycin's serum levels are insufficient for reliable management of pneumococcal bacteremia. This is why parenteral beta-lactams (ceftriaxone, ampicillin-sulbactam) remain the standard for bacteremic pneumococcal infection, and macrolides when added are combined with beta-lactams rather than used as monotherapy for bacteremic disease.
Option A: Option A is incorrect because azithromycin is eliminated primarily unchanged in bile with minimal renal excretion; no dose adjustment is required in renal impairment, and sepsis-associated AKI does not elevate azithromycin to toxic serum levels.
Option B: Option B is incorrect because azithromycin is available in intravenous formulation for patients unable to take oral medications, and the assertion that IV azithromycin has been discontinued in the United States is incorrect; however, even parenteral azithromycin achieves low serum concentrations relative to tissue levels, and the fundamental pharmacokinetic limitation remains.
Option C: Option C is incorrect because the bacteriostatic versus bactericidal distinction is not the pharmacokinetic reason azithromycin is inappropriate for bacteremia; the issue is serum concentration inadequacy, and many bacteriostatic agents (e.g., linezolid) are used successfully for serious systemic infections when serum concentrations are maintained above the MIC.
Option E: Option E is incorrect because azithromycin does not produce transiently very high peak serum concentrations followed by rapid redistribution; its serum concentrations are low throughout the dosing interval because of extensive first-pass tissue uptake, and the argument about concentration-independent kinetics does not correctly describe the actual pharmacokinetic limitation.
11. According to IDSA/ATS consensus guidelines for community-acquired pneumonia (CAP) management, macrolide monotherapy is appropriate for outpatient treatment of low-risk CAP under a specific epidemiological condition. Which of the following correctly states that condition and identifies the preferred alternative when the condition is not met?
A) Macrolide monotherapy is appropriate when the causative organism has been identified as an atypical pathogen (Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella pneumophila) by urinary antigen testing or respiratory PCR, because macrolides provide reliable coverage of atypical organisms regardless of local resistance rates; when a typical pathogen is identified, a beta-lactam must be added
B) Macrolide monotherapy is appropriate only for patients under age 65 with no comorbidities and a CURB-65 score of zero; above this age threshold, combination therapy with a beta-lactam is required to cover drug-resistant Streptococcus pneumoniae (DRSP) regardless of local resistance patterns, because older patients have reduced immunological tolerance for macrolide treatment failures
C) Macrolide monotherapy is appropriate for outpatient low-risk CAP in previously healthy patients without recent antibiotic use when local pneumococcal macrolide resistance rates remain below 25%; when resistance in the community exceeds this threshold, a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is the preferred alternative
D) Macrolide monotherapy is appropriate when the patient has received pneumococcal vaccination within the past five years, because documented vaccine-mediated immunological protection against Streptococcus pneumoniae reduces the probability of treatment failure below the threshold at which clinical guidelines recommend alternative agents
E) Macrolide monotherapy is never appropriate as empiric outpatient CAP therapy because macrolide resistance among S. pneumoniae isolates has uniformly exceeded 25% in all U.S. geographic regions; current IDSA/ATS guidelines recommend a respiratory fluoroquinolone as the sole first-line agent for all outpatient CAP regardless of patient risk category
ANSWER: C
Rationale:
IDSA/ATS consensus guidelines endorse macrolide monotherapy as an appropriate empiric regimen for outpatient CAP in previously healthy adults without recent antibiotic use or risk factors for drug-resistant Streptococcus pneumoniae (DRSP), provided that local pneumococcal macrolide resistance rates remain below 25%. This threshold reflects the point at which empiric macrolide monotherapy produces unacceptably high clinical failure rates. Macrolides are well suited for empiric outpatient CAP monotherapy because they cover both typical respiratory pathogens (S. pneumoniae, H. influenzae for azithromycin and clarithromycin) and atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), eliminating the need for combination therapy in low-risk patients. When local pneumococcal resistance exceeds 25%, a respiratory fluoroquinolone — levofloxacin or moxifloxacin — is the preferred alternative for outpatient monotherapy. For hospitalized CAP patients, macrolines are combined with a beta-lactam rather than used as monotherapy.
Option A: Option A is incorrect because IDSA/ATS guidelines support empiric macrolide therapy without requiring pathogen identification; awaiting microbiological confirmation before initiating antibiotics in outpatient CAP is not standard practice, and the guideline recommendation is based on local resistance surveillance rather than individual organism identification.
Option B: Option B is incorrect because the guideline threshold for macrolide monotherapy appropriateness is based on local pneumococcal resistance rates (25%), not patient age; age-specific resistance thresholds are not part of the current IDSA/ATS framework for this recommendation.
Option D: Option D is incorrect because pneumococcal vaccination status is not the parameter determining macrolide monotherapy appropriateness in IDSA/ATS guidelines; the relevant criterion is local surveillance data on macrolide resistance prevalence among S. pneumoniae isolates.
Option E: Option E is incorrect because macrolide resistance among S. pneumoniae has not uniformly exceeded 25% in all U.S. geographic regions; resistance rates vary substantially by region, and in areas with resistance below 25%, IDSA/ATS guidelines continue to support macrolide monotherapy as an option for low-risk outpatient CAP.
12. A patient with gout managed on long-term colchicine and stage 3 chronic kidney disease (CKD) requires antibiotic therapy for a respiratory infection. Which macrolide is contraindicated in combination with colchicine in a patient with renal impairment, and what dual pharmacokinetic mechanism explains why this combination can be fatal?
A) Clarithromycin is contraindicated with colchicine in renal impairment because clarithromycin simultaneously inhibits both CYP3A4-mediated hepatic metabolism of colchicine and P-glycoprotein (P-gp)-mediated intestinal efflux of colchicine; this dual inhibition multiplies colchicine plasma exposure, and in a patient with reduced renal clearance of colchicine, concentrations accumulate to levels causing severe GI toxicity, bone marrow suppression, myopathy, and potentially death
B) Erythromycin is contraindicated with colchicine specifically in renal impairment because erythromycin's motilin receptor agonism accelerates gastric emptying and dramatically increases the rate of colchicine absorption, producing a toxicokinetic peak concentration exceeding the threshold for colchicine-induced mitotic arrest in bone marrow precursors
C) Azithromycin is contraindicated with colchicine in renal impairment because azithromycin's prolonged 68-hour tissue half-life in phagocytic cells causes sustained delivery of azithromycin to bone marrow macrophages, where it directly inhibits the same microtubule polymerization pathway targeted by colchicine, producing additive bone marrow suppression
D) Clarithromycin is contraindicated with colchicine because clarithromycin competitively inhibits organic anion transporting polypeptide 1B1 (OATP1B1)-mediated hepatic uptake of colchicine, reducing hepatic clearance; renal impairment adds to this because the kidney normally compensates for reduced hepatic uptake through increased urinary colchicine excretion, but this compensatory pathway is also lost in CKD
E) All three macrolides are equally contraindicated with colchicine in renal impairment because all three are potent P-gp inhibitors that increase colchicine absorption; the degree of CYP3A4 inhibition is pharmacologically irrelevant because colchicine's hepatic metabolism by CYP3A4 contributes less than 10% of its total clearance under normal conditions
ANSWER: A
Rationale:
Clarithromycin (and erythromycin) are contraindicated with colchicine in patients with renal or hepatic impairment because of a dual pharmacokinetic interaction that can produce lethal colchicine toxicity. Colchicine depends on two major pathways to limit systemic accumulation: CYP3A4-mediated hepatic metabolism and P-glycoprotein (P-gp)-mediated efflux in the intestinal wall that limits oral absorption. Clarithromycin is a potent inhibitor of both pathways simultaneously. Inhibition of intestinal P-gp increases the fraction of colchicine absorbed per dose, while inhibition of hepatic CYP3A4 reduces clearance of the absorbed drug — a multiplicative increase in colchicine exposure. In a patient with stage 3 CKD, renal clearance of colchicine is already reduced, removing an important compensatory elimination route. The resulting colchicine accumulation produces the classic toxicity syndrome: severe GI toxicity (nausea, vomiting, diarrhea), bone marrow suppression (leukopenia, thrombocytopenia), myopathy, and multi-organ failure — which can be fatal. The FDA label for colchicine contraindicates its use with clarithromycin and erythromycin in patients with renal or hepatic impairment. Azithromycin, which does not significantly inhibit CYP3A4 or P-gp at clinical doses, is the preferred macrolide in patients on colchicine.
Option B: Option B is incorrect because erythromycin's motilin receptor agonism, while it does accelerate gastric emptying, is not the mechanism of the colchicine-macrolide interaction; the interaction is pharmacokinetic (CYP3A4 and P-gp inhibition), not pharmacodynamic motilin-mediated toxicokinetics.
Option C: Option C is incorrect because azithromycin does not inhibit CYP3A4 or P-gp significantly and is the preferred — not contraindicated — macrolide in patients on colchicine; azithromycin does not share the microtubule-disrupting mechanism of colchicine.
Option D: Option D is incorrect because OATP1B1 inhibition is not the primary mechanism of the colchicine-clarithromycin interaction; OATP1B1-mediated hepatic uptake inhibition is the relevant mechanism for interactions involving statins and certain other drugs, but not the dominant pharmacokinetic mechanism of the clarithromycin-colchicine interaction.
Option E: Option E is incorrect because azithromycin does not significantly inhibit P-gp at clinical doses and is explicitly the safe macrolide alternative in patients on colchicine; all three macrolides are not equally contraindicated, and the clinical safety distinction between azithromycin and the other two macrolides in this context is pharmacologically important.
13. Updated CDC sexually transmitted infection treatment guidelines changed the preferred therapy for uncomplicated urogenital Chlamydia trachomatis infection in non-pregnant adults. Which of the following correctly identifies the current preferred regimen and the primary evidence basis for the guideline change?
A) The preferred regimen shifted from doxycycline 100 mg twice daily for 7 days to azithromycin 2 grams as a single dose, because higher single-dose azithromycin produces substantially higher peak intracellular concentrations in genital epithelial cells, achieving microbiologic cure rates exceeding 98% compared to 87% for the lower 1-gram dose that was previously standard
B) The preferred regimen remains azithromycin 1 gram as a single dose for all non-pregnant patients; doxycycline is listed only as an alternative for patients who cannot tolerate macrolides or who have concurrent Mycoplasma genitalium infection confirmed by NAAT (nucleic acid amplification test)
C) The preferred regimen shifted from single-dose azithromycin to levofloxacin 500 mg once daily for 7 days, based on superior microbiologic cure rates for both Chlamydia trachomatis and Mycoplasma genitalium; azithromycin and doxycycline are listed as alternatives for patients with fluoroquinolone allergy or intolerance
D) The preferred regimen shifted from single-dose azithromycin to amoxicillin 500 mg three times daily for 7 days; the guideline change was driven by concerns about azithromycin-associated QTc prolongation in young women, who are at higher risk for drug-induced torsades de pointes and for whom macrolide cardiac risk outweighs benefit
E) The preferred regimen shifted from azithromycin 1 gram as a single dose to doxycycline 100 mg twice daily for 7 days, based on evidence of higher microbiologic cure rates with doxycycline and concerns that single-dose azithromycin drives macrolide resistance selection in concurrent Mycoplasma genitalium infections; azithromycin remains preferred in pregnancy because tetracyclines are contraindicated
ANSWER: E
Rationale:
Updated CDC sexually transmitted infection treatment guidelines (2021 and subsequent revisions) shifted the preferred therapy for uncomplicated urogenital Chlamydia trachomatis infection in non-pregnant adults from azithromycin 1 gram as a single oral dose to doxycycline 100 mg twice daily for 7 days. The change was driven by two lines of evidence: accumulating data showing higher microbiologic cure rates with doxycycline compared to single-dose azithromycin, particularly for rectal chlamydial infections; and mounting concern that empiric single-dose azithromycin therapy for chlamydia was selecting for macrolide resistance in concurrent Mycoplasma genitalium infections, complicating future treatment of that organism in which macrolide resistance is rising significantly. Azithromycin 1 gram single dose remains the preferred regimen for chlamydia in pregnancy, where tetracyclines are contraindicated due to effects on fetal bone and tooth development.
Option A: Option A is incorrect because the guideline shift moved away from azithromycin as the preferred agent, not toward a higher azithromycin dose; the CDC guidelines do not currently recommend 2-gram single-dose azithromycin for chlamydia.
Option B: Option B is incorrect because the current CDC guideline preference is doxycycline as first-line, not azithromycin; this option reverses the actual direction of the guideline change.
Option C: Option C is incorrect because levofloxacin is not the currently preferred regimen for uncomplicated chlamydia; fluoroquinolones were formerly used but are not the primary first-line recommendation in current CDC guidelines for this indication, and the shift described to levofloxacin as preferred does not reflect the actual guideline update.
Option D: Option D is incorrect because amoxicillin is not a recommended agent for uncomplicated urogenital chlamydia in non-pregnant adults in current CDC guidelines; QTc prolongation risk was not the primary driver of the azithromycin-to-doxycycline shift, which was based on efficacy and resistance selection concerns.
14. A patient with disseminated Mycobacterium avium complex (MAC) infection is started on clarithromycin monotherapy. Four weeks later, cultures show high-level clarithromycin resistance. Which of the following correctly identifies both the molecular mechanism by which this resistance emerged and why combination therapy is required to prevent it?
A) Clarithromycin monotherapy selected for MAC organisms that acquired the erm methylase gene through conjugative plasmid transfer from co-colonizing gram-positive organisms; combination therapy with ethambutol prevents plasmid transfer by inhibiting the arabinogalactan cell wall synthesis required for formation of conjugative pili in mycobacteria
B) Clarithromycin monotherapy selected for pre-existing spontaneous point mutations in the 23S rRNA gene at positions 2058 and 2059 in the large bacterial population of disseminated MAC infection; combination therapy with ethambutol and/or rifabutin provides independent bactericidal mechanisms that reduce overall mycobacterial burden and suppress the emergence and expansion of these resistant mutants
C) Clarithromycin monotherapy induced upregulation of the intrinsic mycobacterial MmpL efflux system, which pumps clarithromycin out of MAC organisms with increasing efficiency over successive replication cycles; combination therapy prevents MmpL induction by saturating the efflux system with two additional drug substrates simultaneously
D) Clarithromycin monotherapy caused MAC organisms to switch to a non-replicating persister state with altered ribosomal conformation that reduces macrolide binding; combination therapy with rifabutin specifically activates persister organisms by inhibiting sigma factor-mediated transcription of the persister switch gene, restoring them to a macrolide-susceptible replicating state
E) Clarithromycin monotherapy selected for MAC organisms with amplified copies of the 23S rRNA gene resulting from chromosomal gene duplication; organisms with multiple rRNA gene copies outcompete wild-type organisms because clarithromycin cannot occupy all ribosomal targets simultaneously; combination therapy works by targeting the gene duplication mechanism rather than the ribosomes themselves
ANSWER: B
Rationale:
Macrolide monotherapy for active disseminated MAC is contraindicated because it reliably selects for high-level macrolide resistance. The mechanism is selection of pre-existing spontaneous point mutations in the 23S rRNA gene at positions 2058 and 2059 — the macrolide binding site on the 50S ribosomal subunit. In any large bacterial population, rare spontaneous mutations occur at a predictable frequency; in disseminated MAC — which involves very high mycobacterial burdens across multiple tissues — the absolute number of organisms with 23S rRNA mutations at positions 2058 or 2059 is sufficient that macrolide monotherapy rapidly selects for these pre-existing mutants, allowing them to dominate the population. The resulting high-level resistance (MIC typically exceeding 256 mcg/mL) renders the organisms resistant to the entire macrolide class. These same positions (2058 and 2059) are the sites methylated by erm methylase in MLSB resistance, but in MAC the mechanism is point mutation rather than methylation. Combination therapy with ethambutol (which inhibits arabinogalactan cell wall synthesis) and/or rifabutin (which inhibits RNA polymerase) adds bactericidal mechanisms with independent targets, reducing overall mycobacterial replication and suppressing the selection advantage of resistant mutants. This rationale is analogous to multi-drug therapy for tuberculosis. Macrolide monotherapy is acceptable for primary MAC prophylaxis (CD4 <50 cells/μL) because the goal is prevention of initial infection at low bacterial exposure, not eradication of high-burden established disease.
Option A: Option A is incorrect because erm gene transfer from gram-positive organisms to MAC through conjugative plasmids is not a recognized clinical resistance mechanism; MAC resistance to macrolides occurs through 23S rRNA point mutations, not horizontal erm gene acquisition, and ethambutol inhibits arabinogalactan synthesis for a different purpose than preventing conjugative pili formation.
Option C: Option C is incorrect because MmpL efflux system upregulation is not the primary mechanism of acquired high-level macrolide resistance in MAC; 23S rRNA point mutations are the dominant clinical resistance mechanism, and combination partners do not work by saturating the efflux system.
Option D: Option D is incorrect because MAC does not develop macrolide resistance through persister-state ribosomal conformation changes, and rifabutin does not activate persister organisms through sigma factor mechanisms; the persister concept here is fictitious in the context of macrolide resistance in MAC.
Option E: Option E is incorrect because resistance through amplification of 23S rRNA gene copies is not the mechanism of macrolide resistance in MAC; point mutations in the 23S rRNA gene at specific positions are the established mechanism.
15. An adult patient develops fever, right upper quadrant pain, elevated alkaline phosphatase, elevated bilirubin, and eosinophilia 14 days into a course of erythromycin estolate. Liver biopsy shows cholestasis with periportal inflammation. Which of the following correctly characterizes this adverse effect, identifies the formulation-specific risk, and states the correct implication for future macrolide prescribing?
A) This presentation represents erythromycin-induced toxic hepatocellular necrosis caused by direct mitochondrial toxicity from the nitrosoalkane metabolite of erythromycin formed by CYP3A4; it is equally likely with all erythromycin formulations and with clarithromycin and azithromycin, which share the same metabolic pathway; all macrolides are contraindicated in this patient
B) This presentation represents erythromycin-associated hepatic steatosis caused by inhibition of mitochondrial fatty acid beta-oxidation by the erythromycin estolate ester group; eosinophilia is characteristic and distinguishes this from drug-induced autoimmune hepatitis; the stearate and ethylsuccinate formulations carry equivalent risk
C) This presentation represents erythromycin-associated drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), in which eosinophilia and organ involvement follow a sensitization period; all erythromycin formulations carry equal risk, and the patient should avoid all macrolides and structurally related ketolides permanently
D) This presentation is consistent with erythromycin estolate-associated cholestatic hepatitis, a hypersensitivity reaction that is more common in adults than children, characteristically appears 10 to 20 days after starting therapy, and resolves with drug discontinuation; the reaction is most strongly associated with the estolate ester formulation, which has been largely withdrawn from clinical practice; azithromycin and clarithromycin can be used in this patient with appropriate monitoring
E) This presentation represents erythromycin estolate-induced autoimmune hepatitis in which erythromycin acts as a hapten by covalently binding hepatocyte CYP3A4, creating a neoantigen; the resulting T-cell-mediated attack on hepatocytes is identical to idiopathic autoimmune hepatitis and is treated with corticosteroids; all macrolides that undergo CYP3A4 metabolism are contraindicated
ANSWER: D
Rationale:
Erythromycin estolate-associated cholestatic hepatitis is a well-characterized hypersensitivity reaction with the distinctive clinical features present in this case: right upper quadrant pain, fever, cholestatic liver enzyme pattern (elevated alkaline phosphatase and bilirubin), and eosinophilia — the eosinophilia being particularly characteristic of a hypersensitivity mechanism. The reaction typically appears after 10 to 20 days of therapy, consistent with the sensitization period required for a hypersensitivity reaction, and resolves after drug discontinuation. The reaction is more common in adults than children — an unusual pattern for drug hypersensitivity — and is most strongly associated with the propionate estolate ester formulation of erythromycin. Because of this toxicity, the erythromycin estolate formulation has been largely withdrawn from clinical use in many countries. Azithromycin and clarithromycin can cause hepatotoxicity at lower frequency but tend to produce mixed or hepatocellular rather than purely cholestatic injury; they are not contraindicated based on prior erythromycin estolate exposure, though monitoring is appropriate.
Option A: Option A is incorrect because the reaction is a hypersensitivity phenomenon specific to the estolate formulation, not direct mitochondrial toxicity shared across all macrolides; azithromycin and clarithromycin do not carry the same cholestatic hepatitis risk and are not contraindicated.
Option B: Option B is incorrect because erythromycin estolate hepatitis is not caused by inhibition of mitochondrial beta-oxidation; that mechanism (producing microvesicular hepatic steatosis) is associated with valproic acid and nucleoside reverse transcriptase inhibitors, not macrolides.
Option C: Option C is incorrect because erythromycin estolate hepatitis does not represent DRESS syndrome; DRESS involves a specific constellation of findings (extensive skin rash, lymphadenopathy, multi-organ involvement) distinct from the predominantly hepatic/cholestatic presentation here, and all erythromycin formulations do not carry equal risk.
Option E: Option E is incorrect because erythromycin estolate hepatitis is not classified as CYP3A4 hapten-mediated autoimmune hepatitis, does not respond to corticosteroids as idiopathic autoimmune hepatitis does, and the reaction is formulation-specific (estolate) rather than a class-wide contraindication for all CYP3A4-metabolized macrolides.
16. A patient taking simvastatin, warfarin, and cyclosporine requires empiric macrolide therapy for community-acquired pneumonia. Which macrolide is preferred in this patient, and what is the pharmacokinetic explanation for its safety advantage over the alternatives?
A) Erythromycin is preferred because its short serum half-life of 1.5 to 2 hours means that CYP3A4 inhibition is brief and self-limiting; within 12 hours of the last dose, CYP3A4 activity is fully restored, and interactions with simvastatin, warfarin, and cyclosporine during a standard 7-day course are clinically manageable with daily laboratory monitoring
B) Clarithromycin is preferred because its 14-hydroxyclarithromycin active metabolite does not inhibit CYP3A4 and counteracts the CYP3A4 inhibitory effect of the parent compound through competitive displacement at the enzyme active site, resulting in net CYP3A4 inhibition lower than erythromycin or azithromycin
C) Azithromycin is preferred because it is not substantially demethylated by CYP3A4 and therefore does not generate the nitrosoalkane intermediate that forms an irreversible inhibitory complex with the CYP3A4 heme iron; negligible CYP3A4 inhibition means that simvastatin, warfarin, and cyclosporine concentrations are not meaningfully elevated during the antibiotic course
D) Azithromycin is preferred because its extensive intracellular accumulation in hepatocytes produces competitive substrate inhibition of hepatic CYP3A4 that paradoxically reduces the enzyme's ability to metabolize other substrates; this effect actually lowers plasma concentrations of simvastatin, warfarin, and cyclosporine during treatment, providing a protective rather than harmful interaction
E) All three macrolides are equally safe in this patient because the CYP3A4 interactions with simvastatin, warfarin, and cyclosporine are predictable and uniformly manageable by temporary dose reduction of each affected drug by 50% during the antibiotic course; the choice between macrolides should therefore be based on spectrum of activity and local resistance patterns alone
ANSWER: C
Rationale:
Azithromycin is the correct and preferred macrolide in this polypharmacy patient because it produces negligible CYP3A4 inhibition. The mechanistic reason is that azithromycin is not substantially demethylated by CYP3A4 — unlike erythromycin and clarithromycin, which are both metabolized by CYP3A4 to reactive nitrosoalkane intermediates that form stable, irreversible inhibitory complexes with the ferrous (Fe²⁺) form of CYP3A4. Because azithromycin does not generate this nitrosoalkane intermediate, it does not inactivate CYP3A4 enzyme molecules, and plasma concentrations of CYP3A4-sensitive substrates are not meaningfully elevated. This distinction is clinically critical in this patient: simvastatin accumulation causes myopathy and rhabdomyolysis; elevated warfarin produces supratherapeutic anticoagulation and bleeding; and elevated cyclosporine concentrations in a transplant recipient causes nephrotoxicity and other calcineurin inhibitor toxicities. The three drugs together represent a scenario where erythromycin or clarithromycin could simultaneously precipitate three serious adverse outcomes. Azithromycin's atypical organism coverage (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) is fully adequate for empiric CAP.
Option A: Option A is incorrect because erythromycin's mechanism-based CYP3A4 inhibition is irreversible and does not reverse with drug elimination; CYP3A4 activity is not restored within 12 hours of the last dose — recovery requires new enzyme synthesis over days, and laboratory monitoring does not prevent acute toxicity from drug accumulation during the course.
Option B: Option B is incorrect because 14-hydroxyclarithromycin does not counteract the CYP3A4 inhibitory effect of the parent compound; both clarithromycin and its metabolite inhibit CYP3A4 by the nitrosoalkane mechanism, and the net effect is substantial CYP3A4 inhibition.
Option D: Option D is incorrect because azithromycin's intracellular hepatocyte accumulation does not create competitive substrate inhibition that lowers other drug concentrations; azithromycin does not meaningfully compete with CYP3A4 substrates for enzyme binding, and its hepatic accumulation does not produce the described protective effect.
Option E: Option E is incorrect because the three macrolides are not equally safe in this patient; azithromycin's minimal CYP3A4 inhibition makes it categorically safer, and the interactions with simvastatin, warfarin, and cyclosporine from erythromycin or clarithromycin are not reliably prevented by 50% dose reductions — particularly the irreversible enzyme inactivation pattern of mechanism-based CYP3A4 inhibitors.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.